Roche has licensed two preclinical programmes focused on therapeutics to slow down neurodegenerative disorders from reMYND, a small Belgian biotechnology company. The deal that could be worth more than €500 million to reMYND in milestone and other payments, including an undisclosed upfront payment, plus royalties on any resulting product sales.
The reMYND programmes target the inhibition of alpha-synuclein neurotoxicity in Parkinson's disease and tau neurotoxicity in Alzheimer's disease. As a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?